EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences



The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences



European Journal of Neurology 12(12): 947-955



The increasing use of botulinum toxin type-A, especially for focal dystonia and spasticity has highlighted the issue of secondary non-responsiveness. Within the last few years botulinum toxin type-B (Myobloc(R)(/Neurobloc(R)) has become commercially available as an alternative to type-A. This paper discusses our initial experience of botulinum toxin type-B in a total of 63 individuals who attended our botulinum clinic. Thirty-six patients had cervical dystonia and a secondary non-response to type-A toxin. Thirteen of these patients (36%) had a reasonable clinical response to Neurobloc(R) and continue to have injections. The other 23 patients either had no response, or a poor response, or had unacceptable side effects and ceased treatment. A small number of people with blepharospasm, hemifacial spasm and foot dystonia also had a disappointing response to injection. Twenty patients with spasticity were also type-A resistant. Seven of these show some continuing response to type-B, without unacceptable side effects. These findings demonstrate that botulinum toxin type-B has a place in the management of patients who have become non-responsive to type-A, but overall the responses to type-B toxin were disappointing.

(PDF emailed within 0-6 h: $19.90)

Accession: 012686429

Download citation: RISBibTeXText

PMID: 16324088

DOI: 10.1111/j.1468-1331.2005.01095.x



Related references

Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Laryngoscope 113(4): 743-745, 2003

BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Movement Disorders 12(5): 772-775, 1997

Botulinum toxin type B in patients with botulinum toxin type A antibody-induced therapy failure. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Supplement 2): R18, June, 2002

Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Movement Disorders 8(4): 479-483, 1993

Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group. Wiener Klinische Wochenschrift 111(20): 837-842, 1999

Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department. Vojnosanitetski Pregled 72(12): 1069-1073, 2016

The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatologic Surgery 39(3 Pt 2): 510-525, 2013

First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A. Hno 52(1): 53-56, 2004

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. Journal of Neural Transmission 112(7): 905-913, 2004

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX (R)) in healthy volunteers. Journal of Neural Transmission 112(7): 905-913, 2005

A comparison of water consumption following a single intramuscular injection of equiparalytic doses of NeuroBloc (botulinum toxin type B) and Botox (botulinum toxin type A) in mice. European Journal of Neurology 8(Supplement S4): 25-25, 2001

Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatologic Surgery 29(5): 519-22; Discussion 522, 2003

Spread of paralytic activity of neurobloc (botulinum toxin type B) and botox (botulinum toxin type A) in juvenile monkeys: an electrophysiological model. European Journal of Neurology 8(Supplement S4): 26-26, 2001

Discussion regarding botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Minimal risk of antibody formation after aesthetic treatment with type a botulinum toxin. Facial Plastic Surgery Clinics of North America 17(4): 633-4; Discussion 634-77, Vii, 2010

Initial experiences with clinical use of botulinum toxin type B. Der Nervenarzt 73(2): 194-198, 2002